The $7.8 billion Arcellx exit is the region’s biggest startup success story in years. It also cost 84 people in Rockville their jobs. Here’s how to evaluate a startup offer when both of those things are true.
In 2020, the advice for joining a life sciences startup often came down to one question: Can you stomach the risk? Weigh the science. Weigh the culture. Weigh the equity. And if the risk-reward equation made sense, take the leap.
That advice still holds. But today, that framework is no longer sufficient on its own.
Consider what happened in the BioHealth Capital Region this year. Arcellx – incorporated in Delaware in December 2014 as Encarta Therapeutics, renamed in January 2016, and later built out of a Gaithersburg office on West Watkins Mill Road – followed the trajectory many biotech startups aspire to achieve.
The company raised a $115 million Series C, went public on Nasdaq in February 2022 as a Maryland-headquartered biotech, and secured a major co-development partnership with Gilead’s Kite Pharma. Then, in February 2026, Gilead agreed to acquire Arcellx for $115 per share in cash plus a contingent value right of up to $5 per share, representing an implied equity value of approximately $7.8 billion.
By the traditional startup playbook, that is the outcome everyone is working toward.
Then the deal closed.
Within weeks, Gilead filed WARN notices eliminating 192 positions – 108 in Redwood City, California, and 84 in Rockville, Maryland. Arcellx had reported 209 full-time employees at the end of 2025. The integration effectively brought the standalone organization to an end. BioBuzz examined what that transition meant for the region in The Other Side of Arcellx’s $7.8 Billion Exit.
In this case, the company’s success became a source of workforce disruption.
For anyone weighing a startup offer today, that changes the central question. It is no longer only “Will this company make it?” It is also “What happens to me if it does?”
This guide is built around that second question.
Note: A Series C is a later-stage round of private venture financing. By this point, a startup has typically moved beyond its earliest proof-of-concept stage and is raising significant capital to scale operations, advance clinical or commercial programs, expand its team, or prepare for milestones such as an IPO or acquisition. The lettering reflects the general sequence of institutional fundraising rounds (Series A, Series B, Series C, and sometimes later rounds).
Part 1: Read the Company
Before culture and compensation, do the structural work. Most of it is public. The goal is not to predict exactly what a company will do next, but to understand the signals already in front of you.
Follow the data calendar, not the pitch. Every clinical-stage company runs on readouts. Ask what the next one is, when it lands, and what happens to headcount in both the good and bad scenario. A company with a pivotal readout eighteen months away but only twelve months of cash runway is communicating something important, even if no one says it explicitly.
Read the cash runway. Literally. Public companies disclose it directly. Cartesian Therapeutics, for example, announced in May 2026 that it had secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its expected cash runway into 2028. That is a concrete timeline you can factor into a career decision (and a good example of why runway should be monitored over time rather than treated as a fixed expiration date). Companies can raise additional capital, secure partnerships, reduce spending, or adjust development plans in ways that materially change the picture.
Private companies may not publish the same information, but asking how the business is capitalized and what milestones the current runway is expected to support is entirely reasonable. The quality of the answer can be informative in itself.
Look for the partner already in the building. Arcellx and Kite had been collaborating on anito-cel for years before the acquisition. Strategic partnerships can reduce development and financing risk, but they can also offer clues about the company’s longer-term trajectory and who may ultimately become the natural owner of an asset. That is not necessarily a reason to walk away. It is a reason to understand the ecosystem you are entering.
Watch where headquarters sits. Geography can be an overlooked signal. Arcellx relocated its headquarters from Gaithersburg, MD to Redwood City, CA effective January 30th, 2024 – two years before the acquisition. Maryland shifted from being the center of the company to one of its operating sites. When integration followed, 84 of the 192 positions identified in the WARN notices were based in Rockville. A headquarters move itself does not predict an acquisition or a layoff, but it can signal where leadership, decision-making, and strategically central functions are becoming concentrated and is a leading indicator about whose roles are considered core.
Know where your role sits relative to the asset. In many biotech acquisitions, the buyer is primarily acquiring a therapeutic asset, platform, pipeline, and the expertise needed to advance them. Roles closely connected to the lead program or specialized scientific capabilities may therefore have a different integration profile than functions the acquiring organization already operates at scale. Finance, HR, IT, communications, and other corporate functions can be more exposed to consolidation because overlapping infrastructure already exists. This is not a judgment on the value of that work. It is arithmetic, and you should do it before you accept.
Note: None of these indicators (cash runway, partnerships, headquarters moves, clinical milestones, or organizational structure) can predict an acquisition, restructuring, or layoff on their own. They are signals to consider together, not guarantees of what will happen next. The goal is not to eliminate startup risk, but to understand it well enough to make an informed career decision.
For public companies, much of this information can be found in SEC filings, investor presentations, earnings releases, clinical trial updates, and company announcements. Private companies disclose less, which makes thoughtful questions during the interview process even more important. Cash runway should also be treated as an estimate rather than an expiration date: companies can raise additional capital, reduce spending, secure partnerships, or change development plans.
Part 2: Read the Culture
Structural diligence tells you what could change around you. Culture helps you decide whether the way a company operates fits the way you want to work. And startup cultures can differ far more sharply than candidates expect.
At a BioBuzz CEO Talks event, three founders who built companies in this region described three distinctly different approaches to building and leading startup teams. The years since offer an interesting view of what happened to each company, not because those cultures determined the outcomes, but because the outcomes themselves were impossible for an employee to know when deciding whether to join.
The Mission-Immersive Model: Dr. Murat Kalayoglu, co-founder and former CEO of Cartesian Therapeutics, was direct about what this model demands:
“With Cartesian, I’ve found it particularly difficult to motivate folks that look at careers not as a mission but more as a job. You can’t know that until a person starts working with you… Different people look at work differently. To build a culture based on mission is a real challenge and something I work at every day. The upside of getting people to look at their careers as a mission is enormous.”
“It’s an approach to life and a relationship to work that is very much immersive where it’s okay to do work at 10 pm…where the lines between your personal and work life are completely blurred and you’re okay with it. That kind of attitude is critical. People who try to put a line between the weekend and weekday, day and night, they tend to struggle; not that they can’t do a good job, but long-term it grinds at them and it might be better to go to a bigger company that’s more established.”
The follow-through matters here. In November 2023, Cartesian became a publicly traded company through its merger with Selecta Biosciences and began trading on Nasdaq under the ticker RNAC. Carsten Brunn, Ph.D., became President and CEO of the combined company, while Kalayoglu transitioned to its board of directors before stepping down from the board in March 2026.
The company has continued to advance its lead asset, Descartes-08, which is now in the Phase 3 AURORA trial for generalized myasthenia gravis, alongside clinical programs in myositis and juvenile dermatomyositis. Cartesian, which originated in Gaithersburg, is now headquartered in Frederick, Maryland, where it established a corporate headquarters and cGMP manufacturing facility.
For a candidate, the takeaway is not that an immersive culture is inherently good or bad. It is that founders often tell you very clearly what the organization expects. When a leader describes work as a mission, blurred boundaries as part of the model, or a particular level of personal commitment as essential, take that description seriously. The question is whether that definition of commitment matches the way you want to work.
The Plan-Backward Model: Matt Mulvey took a distinctly different approach at Rockville-based BeneVir Biopharm: start with the intended endpoint and build the company backward from there.
“The way we structured our operations was with a very clear plan. We conceptualized the exit and built the plan from that endpoint. We hired people for different modules of that plan. And we were very clear with people that we wanted them to work 9 to 5 and have the balanced life they need to make it over the long haul. Our plan was seven years. You can’t be a sprinter you have to be able to go the full 26 miles.”
In 2018, that planned exit arrived. Janssen Biotech, part of Johnson & Johnson, acquired BeneVir for $140 million upfront, with up to an additional $900 million tied to development and regulatory milestones, putting the potential value of the transaction at more than $1 billion. BeneVir was still a preclinical-stage company at the time, but its T-Stealth oncolytic virus platform had become strategically valuable to Janssen’s immuno-oncology portfolio.
Importantly, acquisition did not initially mean the disappearance of the local operation. When Janssen announced the deal, it said BeneVir would maintain a research presence in Rockville and become part of the Janssen Oncology Therapeutic Area, with the team continuing its work on the T-Stealth platform and preclinical programs. Johnson & Johnson later confirmed that the acquisition closed during the second quarter of 2018.
Read Mulvey’s words carefully as a candidate: “We hired people for different modules of that plan.” That is an unusually candid description of how startup employment can work. A role can be highly valuable, meaningful, and intentionally built around a particular phase of a company’s development rather than around the assumption of indefinite employment.
Some of the best opportunities in biotech may be exactly that. The issue is not that a role has a defined chapter. The issue is whether you understand what chapter you are being hired to help build, and what may happen when it is complete.
The Execution Model: Greg Merril, then CEO of Adaptive Phage Therapeutics (APT), looked for a different quality in employees: the ability to move from exploration to execution.
“Scientists who come out of an academic environment love research, but at some point, you have to put your pencil down and take that one idea and push it all the way through. They often want to explore new things or ideas, but that’s not going to get you down the road and that’s not the type of people we hire.”
APT’s path illustrates a third kind of startup outcome, one that continued changing even after the acquisition itself.
In March 2024, BiomX acquired APT in a stock-based transaction, making APT a wholly owned subsidiary. Concurrently, BiomX raised approximately $50 million in private financing to support the combined company’s pipeline. Merril joined the BiomX board. But the acquisition was not the end of the story.
In December 2025, BiomX discontinued its BX004 program amid resource constraints and implemented significant workforce reductions. APT’s Gaithersburg lease ended on December 31, 2025. By May 2026, BiomX disclosed that its legacy phage therapy programs had been discontinued, APT was being wound down with only limited grant relationships remaining around its legacy BX011 program, and the parent company had adopted a new strategy focused on defense, security, and critical infrastructure technologies.
That evolution may be the most useful lesson of the three. The point is not that one of these culture models produced a better business outcome than another. Culture and outcome are two different variables. The outcome can change dramatically for reasons far beyond an employee’s control.
Three companies. Three cultures. Three very different trajectories: a multibillion-dollar acquisition followed by the loss of the standalone organization, an independent company continuing to advance a Phase 3 program, and a stock-based acquisition that initially extended the path forward for the combined science before the local operation was ultimately wound down.
None of those outcomes could have been known with certainty from an interview. And that is precisely why culture diligence matters. You cannot control the financing environment, the clinical data, an acquisition, or what a company becomes several years after you join. You can control how carefully you listen when leaders tell you what they expect, and whether the way they work is one you want to work within.
Part 3: Read Your Own Offer
This is where the 2020 version of this framework was thinnest, and where overlooking the fine print can have the greatest financial consequences.
Understand What You Actually Hold. Stock options are not stock. They give you the right to purchase shares at a fixed exercise, or strike, price. Their value depends in part on whether the eventual value of the shares exceeds that price. Restricted stock units (RSUs) work differently and generally do not require you to purchase the underlying shares. Know what type of equity you are being offered, including whether your options are incentive stock options (ISOs) or nonqualified stock options (NSOs), because the mechanics and tax treatment can differ substantially. Know your strike price, vesting schedule, cliff, expiration date, and what happens if your employment ends.
Ask What Happens to Unvested Equity in an Acquisition. This may be one of the most consequential provisions in your equity documents, and many candidates never ask about it. Depending on the plan, award agreement, employment agreement, and terms of an eventual transaction, unvested awards may accelerate, convert into awards of the acquiring company, be cashed out, remain subject to vesting, or be canceled. Some arrangements provide for acceleration upon a change of control itself, often called a single trigger. Others require both a change of control and a qualifying termination, commonly called a double trigger.
Arcellx is a useful example of why the details matter. Under its merger agreement with Gilead, outstanding stock options with exercise prices below the $115-per-share cash consideration were canceled and converted into a cash payment based on the difference between the acquisition price and the exercise price, plus one CVR for each underlying share, whether the options were vested or unvested. Outstanding RSUs, whether vested or unvested, were similarly canceled and converted into the right to receive the cash consideration plus a CVR for each underlying share.
The lesson is not to assume that an acquisition automatically makes your equity valuable, or automatically takes it away. Read the plan and ask exactly what happens to your awards under a change of control.
Understand Contingent Value Rights. In the Arcellx transaction, shareholders received $115 per share in cash plus one contingent value right, or CVR, with the potential to pay an additional $5 per share if anito-cel achieves the specified cumulative worldwide sales milestone by the end of 2029. The CVR is contingent consideration, not guaranteed cash. If a transaction includes a CVR or another milestone-based payment, understand what must happen for it to pay out and evaluate the guaranteed and contingent portions separately.
Check the Post-Termination Exercise Window. If you hold vested options and leave the company, you may have only a limited period to exercise them before they expire under the terms of your plan. Ninety days is common, but it is not universal. There is also an important tax distinction for ISOs: under federal tax rules, exercising generally must occur within three months after employment ends to preserve ISO treatment, although an equity plan may provide a longer contractual exercise period. Exercising can require a significant cash outlay for the strike price and may ceate tax consequences before you have liquidity from the shares. Know the window before you need it.
Price the Cash-versus-Equity Trade Honestly. Taking a lower salary in exchange for more equity is a real financial decision. The salary you give up is guaranteed compensation; the future value of startup equity is not. A lower base can also affect percentage-based bonuses, future raises, retirement contributions, and your earnings over the time you hold the role. Equity can create substantial upside, but do not value it dollar-for-dollar against cash simply because that is how it appears in an offer conversation. Make the trade deliberately, with numbers rather than enthusiasm.
Ask About Severance Before You Need It. Understand whether the company has a documented severance policy, whether different terms apply following a change of control, and whether retention bonuses may be offered during an integration or wind-down. These questions can feel premature when you are excited about an offer. That is exactly why they are worth asking then.
The Arcellx integration shows why. Maryland’s WARN filing lists 84 affected positions at the former Rockville operation, with layoffs staged from June 30, 2026 through April 30, 2027 rather than occurring on a single date. A transition that unfolds over ten months raises practical questions about retention, severance, benefits, equity treatment, and what employees are being asked to stay and complete. The WARN notice does not tell us what individual employees received, but it illustrates why those terms matter long before anyone expects to need them.
You do not need to become an equity expert. You do need to know what you are receiving, when you earn it, what it costs to exercise, what happens if you leave, and what happens if the company is acquired. If you cannot answer those five questions from your offer documents, ask.
Note: This section is intended to help candidates identify questions worth asking; it is not legal, tax, or financial advice. Equity compensation can become complicated quickly, particularly with private-company shares, ISOs, acquisitions, and change-of-control provisions. For an offer with meaningful equity, a short review with a qualified CPA, financial advisor, or employment attorney can be well worth the cost.
Note: Equity Terms in Plain English
Vesting: The process by which you earn ownership of your equity over time.
Cliff: The minimum period you must remain employed before any portion of your equity vests. A one-year cliff is common.
Strike (or Exercise) Price: The price you must pay per share to exercise a stock option.
Vested Equity: Equity you have already earned under your vesting schedule.
Unvested Equity: Equity you have been granted but have not yet earned. What happens to it when you leave or the company is acquired depends on the terms of your plan.
Change of Control: A transaction, such as an acquisition or merger, that results in a change in ownership or control of the company.
Single-Trigger Acceleration: Some or all of your unvested equity vests because a change of control occurs.
Double-Trigger Acceleration: Vesting accelerates only when two events occur – typically a change of control followed by a qualifying termination or significant change to your role within a defined period.
Exercise: Paying the strike price to convert vested stock options into actual shares.
Post-Termination Exercise Window: The amount of time you have after leaving the company to exercise vested options before they expire.
CVR (Contingent Value Right): A right to receive an additional payment in the future if a specified milestone is achieved. The payment is contingent, not guaranteed.
Part 4: Questions to Ask in the Interview
You do not need to ask every question below in a single conversation. Choose the ones most relevant to the role, the company’s stage, and the person you are speaking with. Thoughtful questions like these signal that you are evaluating the opportunity with the same care the company is using to evaluate you.
- What is the next major value-creating milestone, and when do you expect to reach it?
- What is the current cash runway, and what milestones is that runway expected to support?
- How does the company think about financing beyond the current runway?
- Is this role primarily tied to a specific program, or does it support the broader platform or organization?
- Where does decision-making authority sit today, and has that changed as the company has grown?
- How has the size or structure of this team changed over the past eighteen months?
- How are equity awards typically treated in the event of a change of control?
- What is the post-termination exercise window for vested stock options?
- What does the workload for this role look like in practice, particularly during major milestones or high-intensity periods?
- What has turnover on this team looked like over the past year, and what have been the most common reasons people have left?
Note: Not every question belongs with every interviewer. A recruiter or HR partner may be best positioned to answer questions about equity, severance, and benefits. A hiring manager can usually speak more directly to workload, team structure, turnover, and how the role fits the program. Questions about runway, financing, and strategic milestones may be better suited to senior leadership at smaller companies.
Part 5: Build for the Outcome You Cannot Control
Here is the reframe that matters most.
The people leaving Arcellx are not simply a displaced talent pool. They helped take a cell therapy company from early development through late-stage clinical execution, navigating manufacturing scale-up, regulatory complexity, and preparation for commercialization in one of the most technically demanding areas of biopharma. That experience is valuable regardless of what happens to the company that created it.
And for employees who did build meaningful equity during that journey, an acquisition may also create something equally valuable: optionality – the ability to be more deliberate about what comes next.
That is one of the strengths of a mature life sciences ecosystem. Talent recycles. Experienced operators join the next generation of companies, move into the CDMOs, CROs, and other organizations that support them, take on consulting or advisory work, or build something of their own. Some talent will inevitably leave the region, but much of the capability developed inside one company can reappear elsewhere in the ecosystem.
That suggests a different strategy for anyone joining a startup in 2026:
Optimize For What You Take With You. Choose opportunities that build transferable, differentiated capabilities: regulatory strategy in an emerging modality, GMP manufacturing at scale, clinical operations through a pivotal trial, tech transfer, commercialization readiness, or experience taking a program through a major inflection point. Those capabilities remain valuable regardless of the company’s eventual outcome. A title is useful, but what you learned how to do is more durable.
Build The Network Before You Need It. The best time to build professional relationships is while you are still comfortably employed, not after circumstances force you to. Colleagues, former teammates, industry organizations, vendors, partners, and the broader regional community can become sources of information, introductions, opportunities, and support when the landscape changes. Community is career infrastructure, and infrastructure has to be built before you need to rely on it.
Treat Your Career as a Portfolio, Not a Single Bet. That does not mean everyone needs a side business, consulting practice, or advisory role. It means your professional identity should be broader than one employer. Build expertise, relationships, reputation, and experiences that remain yours when the logo on your email signature changes.
The startup leap can still be worth taking. The science being built across this region is ambitious, the upside can be significant, and the breadth of experience available inside a small company can be difficult to replicate elsewhere.
Take the leap with clear eyes about the full range of possible endings and build a career that still works in every one of them.
Resources: Where to Start
BioBuzz is built for exactly this – the career-long path, not the single job search.
Search Verified Roles. The BioBuzz job board features live opportunities across biotech, pharma, medtech, diagnostics, CROs, CDMOs, and advanced manufacturing, with employer-submitted and trusted partner listings designed to reduce ghost postings and spam that often clutter general job boards. AI-powered matching helps surface roles based on your skills, background, and career goals rather than keywords alone.
Create a free account to explore the full board, save opportunities, and apply directly.
Research the Employers, Not Just the Openings. Use verified company pages, regional news coverage, and funding and industry reporting across the BioHealth Capital Region, Greater Philadelphia, and Research Triangle Park to do the diligence described in Part 1. Use these tools to research who is raising capital, advancing programs, signing partnerships, expanding, restructuring, and hiring. Coverage like 5 Top Maryland Cell and Gene Therapy Companies Actively Searching for Talent can provide a starting point.
Get In The Room. BioBuzz events bring 100+ industry professionals, decision-makers, company leaders, recruiters, founders, and community partners together at events throughout the year across BioBuzz markets. That is where the network described in Part 5 gets built – before you need to rely on it.
Early in your Career? The BioCatalyst Workforce Program connects emerging talent from Maryland universities directly with regional employers, industry exposure, and career-building opportunities.
Working Flexibly? A curated Talent Marketplace for part-time, fractional, and project-based work is coming! One verified profile, discoverable by employers looking for specialized talent. Request early access.
More than 30,000 life sciences professionals use BioBuzz to stay connected to this ecosystem. Companies will grow, merge, restructure, and sometimes disappear. Careers will move through more than one of them.
The community is what persists.
Create your free BioBuzz account and be more connected.
Have a startup offer on the table and questions this guide did not answer? Reach out! We regularly talk with professionals navigating these decisions and are always happy to help you think through what to ask next.
